HomeComparePPERF vs ABBV

PPERF vs ABBV: Dividend Comparison 2026

PPERF yields 9.70% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PPERF wins by $356142.93M in total portfolio value
10 years
PPERF
PPERF
● Live price
9.70%
Share price
$0.34
Annual div
$0.03
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$356143.03M
Annual income
$349,225,485,754.62
Full PPERF calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — PPERF vs ABBV

📍 PPERF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPPERFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PPERF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PPERF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PPERF
Annual income on $10K today (after 15% tax)
$824.35/yr
After 10yr DRIP, annual income (after tax)
$296,841,662,891.43/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, PPERF beats the other by $296,841,641,024.56/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PPERF + ABBV for your $10,000?

PPERF: 50%ABBV: 50%
100% ABBV50/50100% PPERF
Portfolio after 10yr
$178071.57M
Annual income
$174,612,755,740.17/yr
Blended yield
98.06%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

PPERF
No analyst data
Altman Z
0.4
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PPERF buys
0
ABBV buys
0
No recent congressional trades found for PPERF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPPERFABBV
Forward yield9.70%3.12%
Annual dividend / share$0.03$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$356143.03M$104.7K
Annual income after 10y$349,225,485,754.62$25,725.73
Total dividends collected$355674.33M$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PPERF vs ABBV ($10,000, DRIP)

YearPPERF PortfolioPPERF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$12,640$1,939.64$11,559$438.51+$1.1KPPERF
2$18,107$4,582.50$13,494$640.86+$4.6KPPERF
3$31,645$12,270.40$15,951$945.97+$15.7KPPERF
4$73,943$40,083.24$19,152$1,413.89+$54.8KPPERF
5$254,186$175,067.16$23,443$2,146.38+$230.7KPPERF
6$1,396,856$1,124,876.96$29,391$3,321.96+$1.37MPPERF
7$13,049,126$11,554,489.43$37,948$5,265.87+$13.01MPPERF
8$215,718,650$201,756,085.36$50,795$8,596.74+$215.67MPPERF
9$6,464,996,099$6,234,177,143.20$71,034$14,549.41+$6464.93MPPERF
10$356,143,031,580$349,225,485,754.62$104,715$25,725.73+$356142.93MPPERF

PPERF vs ABBV: Complete Analysis 2026

PPERFStock

PT Bank Mandiri (Persero) Tbk provides various banking products and services to individuals and businesses in Indonesia, Singapore, Hong Kong, Timor Leste, Shanghai, Malaysia, the United Kingdom, and the Cayman Islands. It offers savings and current accounts, time deposits, demand deposits, and foreign currency savings and current accounts; motorcycle loans, mortgage loan, and housing loans, as well as loans for various purposes, such as education, home renovation, marriage, health, and other needs for individuals; and working capital loans, investment loans, people's business loans, syndicated loans, and micro business loans for businesses. The company also provides investment products comprising mutual funds, stocks, and bond trading; life, health, and general insurance products; credit, debit, and corporate cards; e-banking services; digital lending; cash management services; trade finance services, value chain, supply chain management, global and domestic trade, export and import, standby letter of credit, and bank guarantee, as well as spot and forex services; custodial services; treasury services, including cash transaction/liquidity, hedging, and investment products; trust services comprising trustee, paying agent, security agent, escrow agent, monitoring agent, and receiving bank services; and money transfer, remittance services, and venture capital financing. As of 31 December 2021, it operated 2,609 branches, including 137 branch offices, 2,465 sub-branch offices, and 7 overseas branch offices; and 13,087 ATM facilities. The company was founded in 1998 and is headquartered in Jakarta, Indonesia.

Full PPERF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this PPERF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PPERF vs SCHDPPERF vs JEPIPPERF vs OPPERF vs KOPPERF vs MAINPPERF vs JNJPPERF vs MRKPPERF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.